Harrow Inc - Company Profile
Powered by 
All the data and insights you need on Harrow Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Harrow Inc Strategy Report
- Understand Harrow Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Harrow Inc (Harrow Health) formerly known as Harrow Health Inc, owns a portfolio of healthcare businesses which also includes ImprimisRx, the ophthalmology pharmaceutical compounding business in the US and holds large equity positions in Eton Pharmaceuticals, Melt Pharmaceuticals and Surface Pharmaceuticals. The company is focused on developing innovative medications to serve ophthalmology industry in the marketplace. The company through its subsidiaries develops injectable Dropless Therapy formulations and topical LessDrops formulations. MAY-44 for treating dyspareunia and MAY-88 for treating interstitial cystitis and among others. Harrow Health is headquartered in Nashville, Tennessee, the US.
Headquarters
United States of America
Address
102 Woodmont Blvd, Suite 610, Nashville, Tennessee, 37215
Website
www.harrow.com
Telephone
1 615 7334731
No of Employees
315
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
HROW (NASD)
Revenue (2022)
$130.2M
47%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-73.3%
(2022 vs 2021)
Market Cap*
$363.2M
Net Profit Margin (2022)
XYZ
-17.9%
(2022 vs 2021)
* As of and is in US$
Harrow Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Iheezo | Pharmaceutical Compounding |
| Iopidine | Pharmaceutical Drug Development |
| Maxitrol eye drops | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In July, the company entered into an agreement to acquire the U.S. and Canadian commercial rights for VEVYE (cyclosporine ophthalmic solution) 0.1%. |
| 2022 | Contracts/Agreements | In December, the company agreed to acquire the US rights to Novartis’ ophthalmic products. |
| 2022 | Contracts/Agreements | In November, the company has partnered with iOR to expand national product supply. |
Competitor Comparison
| Key Parameters | Harrow Inc | Trevena Inc | Abbott Medical Optics Inc | Bausch & Lomb Inc | Mastel Precision Surgical Instruments Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Nashville | Chesterbrook | Santa Ana | Bridgewater | Rapid |
| State/Province | Tennessee | Pennsylvania | California | New Jersey | South Dakota |
| No. of Employees | 315 | 23 | - | 12,000 | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mark L. Baum | Chief Executive Officer; Chairman | Executive Board | 2011 | 50 |
| Andrew R. Boll | Secretary; Chief Financial Officer | Senior Management | 2015 | 40 |
| Dennis E. Saadeh | Chief Scientific Officer | Senior Management | 2023 | - |
| John P. Saharek | Chief - Chief Commercial Officer; President - ImprimisRx | Senior Management | 2019 | 63 |
| Kim Barratt | Chief Talent Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer